WTC Health Program Declines to Include Fatty Liver Disease

The World Trade Center Health Program Administrator has rejected requests to add hepatic steatosis, or fatty liver disease, to its list of covered conditions. The decision was based on a lack of sufficient supporting evidence. This outcome affects the eligibility for health benefits for 9/11 responders and survivors.

Context

The World Trade Center Health Program was established to provide medical monitoring and treatment for health conditions linked to the 9/11 attacks. Hepatic steatosis, commonly known as fatty liver disease, has been reported among some responders and survivors. The program's administrator determined that there was insufficient evidence to warrant its inclusion as a covered condition.

Why it matters

The decision not to include fatty liver disease in the World Trade Center Health Program is significant as it impacts the health benefits available to 9/11 responders and survivors. Many individuals who were exposed to toxic substances may experience this condition. The ruling reflects the ongoing challenges in addressing health issues related to the September 11 attacks.

Implications

The exclusion of fatty liver disease from the program may leave some responders and survivors without necessary medical support. This decision could lead to increased health disparities among those affected by 9/11-related illnesses. Additionally, it may influence public perception and advocacy efforts regarding the health impacts of the attacks.

What to watch

In the near term, advocates for 9/11 responders may push for further research to establish a clearer connection between fatty liver disease and exposure to World Trade Center toxins. Future meetings or reports from the health program could provide updates on potential reconsiderations. Legislative actions may also emerge as stakeholders seek to expand health benefits.